Clinical efficacy of sitafloxacin 100 mg twice daily for 7 days for patients with non-gonococcal urethritis

Abstract

To clarify the clinical efficacy of STFX for patients with non-gonococcal urethritis (NGU), including chlamydial urethritis and Mycoplasma genitalium-positive urethritis, this study included male patients with NGU who were 20 years old or older. The pathogens, including Chlamydia trachomatis, M. genitalium and Ureaplasma urealyticum, were detected by nucleic acid amplification tests and the patients were treated with sitafloxacin 100 mg twice daily for 7 days. Microbiological and clinical efficacies were assessed for the patients with NGU posttreatment. Among the 208 patients enrolled in this study, data for a total of 118 patients could be analyzed. The median age was 32 (20-61) years. The median duration from the completion of treatment to the second visit was 21 (14-42) days. There were 68 pathogen-positive NGU cases and 50 with NGU without any microbial detection. Microbiological cure was achieved in 95.6% of the pathogen-positive NGU patients. Total clinical cure was achieved in 91.3% (105/115). In this study, STFX was able to eradicate 95.7% of C. trachomatis, 93.8% of M. genitalium and 100% of U. urealyticum. The results of our clinical research indicate that the STFX treatment regimen should become a standard regimen recommended for patients with NGU. In addition, this regimen is recommended for patients with M. genitalium-positive NGU.

In vitro activity and time‐kill curve analysis of sitafloxacin against a global panel of antimicrobial‐resistant and multidrug‐resistant Neisseria gonorrhoeae isolates

“…Finally, sitafloxacin has additionally high activity against Chlamydia trachomatis and Mycoplasma genitalium , frequent aetiological agents of non‐gonococcal urethritis and cervicitis. In two studies published in 2012 and 2013, sitafloxacin 100 mg twice daily orally for 7 days eradicated 95.7–100% and 93.8–100% of C. trachomatis and M. genitalium infections, respectively .…”

Genetic Variation inMycoplasma genitalium

“…Some quinolones, such as moxifloxacin, have potent activity in vivo and in vitro against MG, and treatment with moxifloxacin is considered as an effective second-line treatment for azithromycin-resistant, persistent or recurrent MG infections [54,71]. The antibacterial activities of the quinolones may be due to their inhibitory activities against bacterial type II topoisomerases, such as DNA gyrase and topoisomerase IV (Table 6) [54,[67][68][69]71,72].…”

“…The antibacterial activities of the quinolones may be due to their inhibitory activities against bacterial type II topoisomerases, such as DNA gyrase and topoisomerase IV (Table 6) [54,[67][68][69]71,72]. Therefore, it has been reported that mutations in the quinolone resistance-determining regions of the type II topoisomerases contribute to quinolone resistance in various bacterial species, including MG [67][68][69].…”

Nichtgonorrhoische infektiöse Urethritis

“…[7]. Bei Zunahme von Resistenzbildungen muss der Stellenwert von anderen Medikamenten wie Sitafloxacin oder Gatifloxacin weiter untersucht werden [10,27], um eine drohende Unbehandelbarkeit von M. genitalis abzuwenden [28].…”